Literature DB >> 19688152

Chronic urticaria is usually associated with fibromyalgia syndrome.

Claudio Torresani1, Salvatore Bellafiore, Giuseppe De Panfilis.   

Abstract

Although the pathophysiology of chronic urticaria is not fully understood, it is possible that dysfunctioning of peripheral cutaneous nerve fibres may be involved. It has also been suggested that fibromyalgia syndrome, a multi-symptomatic chronic pain condition, may be associated with alterations and dysfunctioning of peripheral cutaneous nerve fibres. The aim of this study was to determine whether patients with chronic urticaria are also affected by fibromyalgia syndrome. A total of 126 patients with chronic urticaria were investigated for fibromyalgia syndrome. An unexpectedly high proportion (over 70%) had fibromyalgia syndrome. The corresponding proportion for 50 control dermatological patients was 16%, which is higher than previously published data for the Italian general population (2.2%). It is possible that dysfunctional cutaneous nerve fibres of patients with fibromyalgia syndrome may release neuropeptides, which, in turn, may induce dermal microvessel dilatation and plasma extravasation. Furthermore, some neuropeptides may favour mast cell degranulation, which stimulates nerve endings, thus providing positive feedback. Chronic urticaria may thus be viewed in many patients, as a consequence of fibromyalgia syndrome; in fact, skin neuropathy (fibromyalgia syndrome) may trigger neurogenic skin inflammation (chronic urticaria).

Entities:  

Mesh:

Year:  2009        PMID: 19688152     DOI: 10.2340/00015555-0653

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  12 in total

1.  The development and psychometric validation of the central sensitization inventory.

Authors:  Tom G Mayer; Randy Neblett; Howard Cohen; Krista J Howard; Yun H Choi; Mark J Williams; Yoheli Perez; Robert J Gatchel
Journal:  Pain Pract       Date:  2011-09-27       Impact factor: 3.183

2.  Celiac symptoms in patients with fibromyalgia: a cross-sectional study.

Authors:  Juan Miguel García-Leiva; Jorge Luis Ordóñez Carrasco; Mahmoud Slim; Elena P Calandre
Journal:  Rheumatol Int       Date:  2014-08-15       Impact factor: 2.631

Review 3.  Central sensitization: implications for the diagnosis and treatment of pain.

Authors:  Clifford J Woolf
Journal:  Pain       Date:  2010-10-18       Impact factor: 6.961

4.  Psychosomatic factors in pruritus.

Authors:  Hong Liang Tey; Joanna Wallengren; Gil Yosipovitch
Journal:  Clin Dermatol       Date:  2013 Jan-Feb       Impact factor: 3.541

Review 5.  Fibromyalgia syndrome in need of effective treatments.

Authors:  Theoharis C Theoharides; Irene Tsilioni; Lauren Arbetman; Smaro Panagiotidou; Julia M Stewart; Rae M Gleason; Irwin J Russell
Journal:  J Pharmacol Exp Ther       Date:  2015-08-25       Impact factor: 4.030

6.  Neuropeptides CRH, SP, HK-1, and Inflammatory Cytokines IL-6 and TNF Are Increased in Serum of Patients with Fibromyalgia Syndrome, Implicating Mast Cells.

Authors:  Irene Tsilioni; Irwin J Russell; Julia M Stewart; Rae M Gleason; Theoharis C Theoharides
Journal:  J Pharmacol Exp Ther       Date:  2016-01-13       Impact factor: 4.030

7.  The evaluation of prevalence of fibromyalgia in patients with chronic urticaria.

Authors:  Mahmut Yener; Ijlal Erturan; Ali Murat Ceyhan; Esra Erkol Inal; Oya Oylum Kazanoglu
Journal:  Med Sci Monit       Date:  2013-09-11

8.  Chronic urticaria.

Authors:  Sandeep Sachdeva; Vibhanshu Gupta; Syed Suhail Amin; Mohd Tahseen
Journal:  Indian J Dermatol       Date:  2011-11       Impact factor: 1.494

9.  High Frequency of Fibromyalgia in Patients With Acne Vulgaris.

Authors:  Levent Yazmalar; Tahsin Çelepkolu; İbrahim Batmaz; Mustafa Akif Sariyildiz; Bilal Sula; Mahmut Alpayci; İsa An; Yahya Kemal Burkan; Haydar Uçak; Remzi Çevik
Journal:  Arch Rheumatol       Date:  2016-02-22       Impact factor: 1.472

10.  Ambroxol for the treatment of fibromyalgia: science or fiction?

Authors:  Kai-Uwe Kern; Myriam Schwickert
Journal:  J Pain Res       Date:  2017-08-16       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.